You are here

Price rise for anti-allergy EpiPen sparks furore

Fivefold price hike of epinephrine injector makes it unaffordable to many US sufferers

Washington

A FIVEFOLD price hike for EpiPen, which allergy sufferers use to counteract life-threatening reactions, has made Mylan the newest drugmaker to come under attack in the United States for profiteering.

Mylan Pharmaceuticals, which holds a near-monopoly position on the

sentifi.com

Market voices on:

Powered by GET.comGetCom